One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
REGENXBIO  logo
REGENXBIO RGNX
$ 7.16 -1.1%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

REGENXBIO Income Statement 2025-2011 | RGNX

Brief overview of income trends at REGENXBIO

This overview is based on financial performance over the past five years. The revenue attributed to REGENXBIO moved from 155 million dollars to 170 million dollars between the two endpoints. Overall revenue changed by +10.3%, equal to an annualized rate of about 2%. The revenue trend is close to stagnation.

The operating result measured by EBITDA moved from −$111 million to −$146 million, or −31.4%. Operating performance weakened relative to revenue. At the operating-margin level, the figure shifted from −71.7% to −85.4%. Cost pressure reduced operating profitability.

Comparing the endpoints shows a move from −111 million dollars to −194 million dollars. The period ended with a larger loss than it began with.

The five-year change in capitalization reached −70.9%: from 1.5 billion dollars to 444 million dollars. Lower capitalization reflects weaker investor expectations.

What the figures show

The current trajectory does not yet confirm a sustainable recovery. Caution is warranted because of weak sales momentum, a declining EBITDA margin and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement REGENXBIO

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

444 M 426 M 872 M 958 M 1.11 B 1.53 B 1.63 B 1.44 B 844 M 479 M 128 M - - - -

Shares

51.6 M 49.5 M 43.7 M 43.2 M 42.4 M 37.3 M 36.7 M 33.4 M 29.9 M 26.4 M 9.17 M - - - -

Historical Prices

8.6 8.6 19.9 22.2 26.2 40.9 40 51.7 28.4 18.4 12.1 - - - -

Net Income

-194 M -227 M -263 M -280 M 128 M -111 M -94.7 M 99.9 M -73.2 M -63 M -22.8 M -4 M -5.39 M - -

Revenue

170 M 83.3 M 90.2 M 113 M 470 M 155 M 35.2 M 219 M 10.4 M 4.59 M 7.59 M 6.12 M 6.09 M - -

Cost of Revenue

- 33.6 M 37.2 M 54.5 M 51.8 M 35.7 M 8.24 M 9.64 M 1.71 M - - - - - -

Gross Profit

- 49.8 M 53 M 58.2 M 419 M 119 M 27 M 209 M 8.68 M 3.63 M 6.08 M 5.11 M 5.76 M - -

Operating Income

-161 M -233 M -268 M -263 M 160 M -119 M -149 M 88.1 M -75.9 M -65.3 M -23.1 M -3.68 M -4.78 M - -

Interest Expense

- - 6.86 M 23.3 M 26.3 M 771 K - - - - 20 K 321 K 611 K - -

EBITDA

-146 M -217 M -251 M -250 M 170 M -111 M -142 M 92.1 M -73.2 M -64.8 M -23 M -3.65 M -4.76 M - -

Operating Expenses

161 M 283 M 321 M 321 M 259 M 238 M 176 M 121 M 84.6 M 69 M 29.2 M 8.76 M 10.5 M - -

General and Administrative Expenses

82.9 M 76.6 M 88.5 M 85.3 M 79.3 M 63.8 M 51.8 M 36.8 M 27.2 M 23.6 M 11.9 M 3.85 M 5.47 M - -

All numbers in USD currency

Quarterly Income Statement REGENXBIO

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

65.3 M 52.8 M 52.4 M 60 M 51.7 M 51.5 M 51.4 M 458 K 50.8 M 50.6 M 45.7 M 90 K 43.9 M 43.5 M 43.5 M 43.1 M 43.3 M 43.1 M 42.9 M 42.4 M 42.6 M 42.5 M 41.8 M 47 M 37.3 M 37.3 M 37.1 M 72 K 36.8 M 36.7 M 36.4 M 851 K 34 M 32.1 M 31.6 M 438 K 30.9 M 30.7 M 26.7 M 26.5 M 26.5 M 26.4 M 26.3 M 26.3 M 4.81 M 2.71 M 2.64 M 2.64 M 2.64 M - - - - - - - - - - - - - -

Net Income

-40.7 M 22.7 M -90.1 M -67.1 M -61.9 M -70.9 M 6.08 M -51.2 M -59.6 M -53 M -63.3 M -62.9 M -61.9 M -72.1 M -66.7 M -59.9 M -75.5 M -68.2 M -76.7 M 294 M -58.4 M -57.6 M -50.1 M -46.2 M 8.79 M -33.8 M -40 M -26.5 M -34.6 M -1.46 M -32.2 M 4.31 M -19.2 M 10.6 M 104 M -16 M -20.7 M -14.5 M -22 M -19.6 M -18.2 M -14.4 M -10.8 M -5.18 M -7.33 M -6.29 M -4.01 M -2.33 M -1.79 M -672 K 795 K - - - - - - - - - - - -

Revenue

9.16 M 108 M 6.39 M 30.3 M 29.7 M 21.4 M 89 M 21.2 M 24.2 M 22.3 M 15.6 M 22.2 M 28.9 M 20 M 19.1 M 31.3 M 26.5 M 32.6 M 22.2 M 403 M 30.3 M 18.4 M 18.3 M 21.4 M 98.8 M 15.4 M 9.98 M 11.8 M 9.18 M 4.42 M 884 K 40.8 M 4 M 40 M 132 M 2.04 M 1.34 M 6.56 M 455 K 1.7 M 125 K 2.38 M 393 K 4.44 M 1.14 M 1.36 M 644 K 1.15 M 483 K 1.55 M 2.94 M - - - - - - - - - - - -

Cost of Revenue

- - - - - - - 6.32 M 12.4 M 10.6 M 4.28 M 11.2 M 12.4 M 9.48 M 4.11 M 12.8 M 13.1 M 13 M 15.7 M 23.1 M 14.1 M 9.82 M 4.85 M 10.3 M 17.4 M 4.68 M 3.41 M 3.79 M 2.49 M 1.93 M 29 K 2.84 M 517 K 3.87 M 2.41 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - 14.9 M 11.8 M 11.7 M 11.3 M 11 M 16.5 M 10.5 M 15 M 18.6 M 13.4 M 19.7 M 6.5 M 380 M 16.1 M 8.61 M 13.4 M 11.2 M 81.4 M 10.8 M 6.57 M 7.98 M 6.69 M 2.5 M 855 K 37.9 M 3.48 M 36.2 M 130 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-35.5 M 29.3 M -83.4 M -57.6 M -52.4 M -63.3 M 12.1 M -51.4 M -62.1 M -56 M -63.9 M -63.9 M -65 M -73.1 M -66.2 M -57.8 M -71 M -62.5 M -71.5 M 314 M -57.3 M -52.2 M -44 M -53.7 M 14 M -41.8 M -37.7 M -40.3 M -35.9 M -36.9 M -35.9 M 2.45 M -22.7 M 6.35 M 102 M -16.6 M -21.3 M -15.1 M -22.9 M - -18.7 M -15 M -11.3 M - -7.35 M -6.3 M -3.99 M - -1.7 M - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - 449 K 1.97 M 1.36 M 1.62 M 1.12 M 2.76 M 4.31 M 5.95 M 6.86 M 6.13 M 6.5 M 6.71 M 6.37 M 6.7 M - - - - - - - - - - - - - - - - - - - 483 K - 20 K 20 K 20 K - 92 K - - - - - - - - - - - - - -

EBITDA

-35.5 M 33 M -79.5 M -53.8 M -48.5 M -59.4 M 16.1 M -47.3 M -58.1 M -52 M -59.7 M -59.6 M -60.6 M -68.7 M -62 M -53.6 M -67.5 M -59.9 M -68.9 M 316 M -54.5 M -50 M -42.1 M -51.5 M 16.1 M -39.7 M -35.7 M -38.4 M -34 M -35.1 M -34.3 M 3.76 M -21.8 M 7.25 M 103 M -15.9 M -20.6 M -14.4 M -22.4 M - -18.4 M -14.9 M -11.2 M - -7.3 M -6.28 M -3.99 M - -1.7 M - - - - - - - - - - - - - -

Operating Expenses

- -29.3 M 83.4 M - 52.4 M 63.3 M -12.1 M 66.3 M 73.9 M 67.8 M 75.2 M 74.9 M 81.5 M 83.6 M 81.2 M 76.3 M 84.5 M 82.2 M 78 M 66.7 M 73.5 M 60.8 M 57.5 M 64.8 M 67.5 M 52.6 M 44.3 M 48.3 M 42.6 M 39.4 M 36.8 M 35.5 M 26.2 M 29.8 M 28 M 16.6 M 21.3 M 15.1 M 22.9 M - - 15 M 11.3 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

20.6 M 21.6 M 21.3 M 22.4 M 20.3 M 19.9 M 20.3 M 20.1 M 19.4 M 18.9 M 18.3 M 19.1 M 23.1 M 23.7 M 22.6 M 21.2 M 20.9 M 20.8 M 22.3 M 22 M 21 M 18.4 M 17.8 M 17.6 M 15.9 M 15.6 M 14.8 M 14.4 M 12.4 M 13.4 M 11.6 M 11.1 M 9.01 M 8.32 M 8.38 M 4.81 M 9.44 M 6.36 M 6.62 M 5.74 M 6.2 M 6.17 M 5.48 M 4.23 M 2.57 M 3.4 M 1.72 M - 1.07 M - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company REGENXBIO (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 3.97 0.89 % $ 324 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 129.32 -4.69 % $ 6.43 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 75.96 -2.84 % $ 14.5 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.23 -1.3 % $ 1.52 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 2.89 -5.25 % $ 200 M britainBritain
Benitec Biopharma Benitec Biopharma
BNTC
$ 7.95 -2.4 % $ 370 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 8.24 2.74 % $ 387 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 141.06 -2.35 % $ 28.1 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 6.9 -5.61 % $ 2.47 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.64 17.17 % $ 56.6 M israelIsrael
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 15.56 13.57 % $ 64.8 M canadaCanada
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 12.36 -9.55 % $ 799 M usaUSA
Immutep Limited Immutep Limited
IMMP
$ 3.11 -9.06 % $ 4.53 B australiaAustralia
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 228.26 -3.46 % $ 13.9 B irlandaIrlanda
BeyondSpring BeyondSpring
BYSI
$ 0.33 -24.42 % $ 13.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 0.94 -7.24 % $ 94.5 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
$ 1.0 -5.17 % $ 87.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 7.75 -1.02 % $ 447 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.83 -2.66 % $ 171 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.37 -4.06 % $ 43.3 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.36 -2.15 % $ 1.82 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.9 -9.7 % $ 90.3 M franceFrance
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.01 -7.59 % $ 11.4 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 345.4 -0.44 % $ 1.21 T usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.73 -1.9 % $ 783 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.32 1.02 % $ 2.52 M israelIsrael
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 2.05 -15.81 % $ 27.3 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 76.99 0.03 % $ 997 M usaUSA
Curis Curis
CRIS
$ 0.44 -6.31 % $ 5.79 M usaUSA
CorMedix CorMedix
CRMD
$ 5.25 4.23 % $ 378 K usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
$ 3.07 -4.66 % $ 255 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.34 -1.36 % $ 60 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 10.9 -2.5 % $ 13.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 96.15 0.67 % $ 4.83 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.85 -2.66 % $ 1.18 B usaUSA
Dyadic International Dyadic International
DYAI
$ 0.29 -6.53 % $ 10.5 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 133.34 0.4 % $ 334 B usaUSA
Moderna Moderna
MRNA
$ 195.25 -2.05 % $ 76 B usaUSA
NuCana plc NuCana plc
NCNA
$ 0.75 4.39 % $ 8.42 B britainBritain
Novartis AG Novartis AG
NVS
$ 150.51 -0.47 % $ 292 B schweizSchweiz
Puma Biotechnology Puma Biotechnology
PBYI
$ 7.05 -1.05 % $ 353 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.69 -0.67 % $ 281 M usaUSA